From: "Meredith Sutherland" <sutherland_nn@stamm-chatten.de>
To: rda@sources.redhat.com
Subject: Watch this St0ckTcrade
Date: Wed, 05 Oct 2005 11:11:00 -0000 [thread overview]
Message-ID: <ec1401c5c994$c0cb908b$f1bda7f9@emails.de> (raw)
ATTENTION INVESTING PUBLIC
ASCE . PK
Recent Trading Range: $.80 - $.90
Expected Trading Range: $1.50 - $2.00
ASCE . PK
BELLEVUE, WA. September 14, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious
pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research
particularly in anti-cancer compounds and for organizational growth.
BELLEVUE, WA. September 27th, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious
pharmaceuticals, compounds and other products, announces the addition of Dr. Philip Mease to its Scientific Advisory Board. Dr. James Clagett,
President and CEO of Ascentia said, .We are privileged to have such an internationally recognized rheumatologist who has a distinguished career in the
clinical development of therapies for rheumatic diseases. Dr. Mease.s experience in clinical drug discovery along with his respected relationship with
drug regulatory agencies will greatly assist Ascentia in its drug discovery and commercialization program..
Dr. Mease is Chief of the Rheumatology Clinical Research Division at Swedish Hospital, Clinical Professor at the University of Washington, and founder
of Seattle Rheumatology Associates. Dr. Mease graduated from Stanford University Medical School and completed his medical training at University of
Washington, Seattle.
About Ascentia Biomedical Corporation
Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for
application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer. Initially, a majority of these products will be
secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused
on therapies for cancer and diseases of inflammation.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks
and uncertainties. These statements do not constitute representations
or promises. Rather, these statements express opinions, hopes and
desires that may not be based on objective or factual criteria or
measurable results. No one should rely on such statements for any
purpose except as specifically stated
To get taken off the list email NOSTK@Yahoo.com
reply other threads:[~2005-10-05 11:11 UTC|newest]
Thread overview: [no followups] expand[flat|nested] mbox.gz Atom feed
Reply instructions:
You may reply publicly to this message via plain-text email
using any one of the following methods:
* Save the following mbox file, import it into your mail client,
and reply-to-all from there: mbox
Avoid top-posting and favor interleaved quoting:
https://en.wikipedia.org/wiki/Posting_style#Interleaved_style
* Reply using the --to, --cc, and --in-reply-to
switches of git-send-email(1):
git send-email \
--in-reply-to='ec1401c5c994$c0cb908b$f1bda7f9@emails.de' \
--to=sutherland_nn@stamm-chatten.de \
--cc=rda@sources.redhat.com \
/path/to/YOUR_REPLY
https://kernel.org/pub/software/scm/git/docs/git-send-email.html
* If your mail client supports setting the In-Reply-To header
via mailto: links, try the mailto: link
Be sure your reply has a Subject: header at the top and a blank line
before the message body.
This is a public inbox, see mirroring instructions
for how to clone and mirror all data and code used for this inbox;
as well as URLs for read-only IMAP folder(s) and NNTP newsgroup(s).